Next Article in Journal
Non-Invasive Physical Plasma Reduces the Inflammatory Response in Microbially Prestimulated Human Gingival Fibroblasts
Next Article in Special Issue
Gut Microbiota and Mitochondria: Health and Pathophysiological Aspects of Long COVID
Previous Article in Journal
Uncovering the Genetic and Molecular Features of Huntington’s Disease in Northern Colombia
Previous Article in Special Issue
Elevated Liver Fibrosis Progression in Isolated PSC Patients and Increased Malignancy Risk in a PSC-IBD Cohort: A Retrospective Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 22
10.3390/ijms242216155
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Inactivation of Group 1B Phospholipase A2 Enhances Disease Recovery and Reduces Experimental Colitis in Mice

by
April M. Haller
1,
Patrick R. Wolfkiel
2,
Anja Jaeschke
1 and
David Y. Hui
1,*
1
Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, OH 45237, USA
2
Molecular Genetics, Biochemistry and Microbiology Graduate Program, University of Cincinnati, Cincinnati, OH 45267, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(22), 16155; https://doi.org/10.3390/ijms242216155
Submission received: 20 October 2023 / Revised: 4 November 2023 / Accepted: 6 November 2023 / Published: 10 November 2023
(This article belongs to the Special Issue Gut and the Liver in Health and Disease 2.0)
Browse Figures
Versions Notes

Abstract

:
Phospholipase A2 (PLA2) enzymes influence inflammatory bowel disease in both positive and negative manners depending on the type of PLA2 that is expressed. This study explored the influence of the abundantly expressed Group 1B PLA2 (PLA2G1B) on ulcerative colitis. Wild-type C57BL/6J mice and Pla2g1b−/− mice were treated with dextran sulfate sodium (DSS) for 5 days to induce epithelial injury, followed by another 5 days without DSS for recovery. The Pla2g1b−/− mice displayed significantly less body weight loss, colitis pathology, and disease activity indexes compared to the wild-type mice. The differences in colitis were not due to differences in the colonic lysophospholipid levels, but higher numbers of stem and progenitor cells were found in the intestines of Pla2g1b−/− mice compared to the wild-type mice. The DSS-treated Pla2g1b−/− mice also showed higher expressions of genes that are responsible for epithelial repair and lower expressions of proinflammatory cytokine genes in the colon, as well as reduced inflammatory cytokine levels in the plasma. In vitro experiments revealed the PLA2G1B stimulation of inflammatory cytokine expression by myeloid cells. PLA2G1B inactivation protects against DSS-induced colitis in mice by increasing the intestinal stem cell reservoir for epithelial repair and reducing myeloid cell inflammation in the diseased colon. Thus, PLA2G1B may be a target for colitis management.

1. Introduction

Ulcerative colitis is a chronic inflammatory disease of the gastrointestinal tract with unknown etiology. Pathologically, it is characterized by colonic mucosal injury and immune cell infiltration to exacerbate tissue inflammation and crypt destruction. Major risk factors for ulcerative colitis include genetic predisposition, childhood environment, stress, intestinal dysbiosis, and the chronic consumption of a high-fat diet [1,2,3,4]. Several studies indicated that differences in the lipid and amino acid metabolisms in the digestive tract may be key determinants of inflammatory bowel disease [5,6]. In particular, the lipidomic profiling of intestinal and colonic mucosa revealed significantly lower levels of phosphatidylcholine (PC) and the corresponding increase in the lysophosphatidylcholine (LPC) levels in colitis patients compared to the control subjects [6,7]. These observations led to the hypothesis that enzymes that are responsible for PC hydrolysis to LPC may be involved in the pathogenesis of ulcerative colitis [7].
Enzymes that hydrolyze PC to LPC are members of the phospholipase A2 (PLA2) superfamily that includes six major classes based on their cellular locations. These include the secretory PLA2 enzymes, which hydrolyze extracellular phospholipids to lysophospholipids, as well as intracellular enzymes such as the cytosolic PLA2 and the calcium-independent PLA2, which hydrolyze phospholipids in different intracellular compartments [8]. The products of PLA2 reactions, lysophospholipids, and nonesterified fatty acids, are bioactive lipid metabolites that serve as intracellular and extracellular signals in regulating cell functions and pathophysiological process such as obesity/diabetes, cardiovascular disease, cancer, neurodegenerative disorders, and inflammatory bowel disease [9]. These lipid metabolites may also serve as substrates for the synthesis of other active lipid metabolites such as prostaglandins, thromboxane, leukotrienes, and epoxyeicosatrienoic acids that modulate cardiometabolic and inflammatory disease pathogenesis [10].
Several PLA2 enzymes have been shown to influence inflammatory diseases in the gastrointestinal tract. Interestingly, various PLA2 enzymes appeared to influence inflammatory bowel disease in opposing manners depending on the cell type and where the enzyme is expressed. For example, the calcium-independent Group VIA PLA2, which is expressed intracellularly in the colon, was shown to protect against inflammatory bowel disease, and its deletion in mice increased the susceptibility to chemical-induced colitis [11]. In contrast, the cytosolic Group IVA PLA2 increases colonic inflammation, and its inactivation is beneficial in suppressing inflammatory bowel disease [12,13]. Likewise, whereas the secretory Group III PLA2 is proinflammatory and its inactivation protects mice against chemical-induced colitis [14], the Group X secretory PLA2 (PLA2G10) expressed in non-hematopoietic but not hematopoietic cells is anti-inflammatory and also protects against colitis [15,16]. The secretory Group IIA PLA2 (PLA2G2A), which is absent in C57BL/6 mice, the most commonly used mouse model to study disease pathogenesis, was also found to be proinflammatory and promotes colitis when overexpressed in C57BL/6 mice [16]. Moreover, the selective inhibition of PLA2G2A was also found to reduce colitis in rats [17]. The lack of this enzyme in Pla2g10-null mice displayed improved inflammatory responses compared to Pla2g10-null mice with PLA2G10A expression [16].
One of the most abundant PLA2 enzymes in the digestive tract is the Group 1B PLA2 (PLA2G1B), which is secreted by the pancreas into the intestinal lumen in response to food intake. We have previously shown that PLA2G1B hydrolyzes phospholipids to lysophospholipids during food digestion to aid in lipid absorption, and the resulting lysophospholipids are transported to the liver to reduce fatty acid oxidation and cause mitochondria dysfunction, thereby promoting hyperlipidemia, obesity/diabetes, and atherosclerosis [18,19,20,21,22]. Interestingly, despite its role in metabolic disease pathogenesis and despite the fact that its inactivation is protective against diet-induced cardiometabolic diseases [23], PLA2G1B that is expressed in the pancreas and intestinal epithelial cells also has health benefits, including its anthelmintic properties that protect the gut epithelium from repeated helminth infection after initial anthelmintic treatment [24]. Its anthelmintic property is unrelated to the adaptive and innate immunity of the host, but it is due to PLA2G1B’s killing of the larvae by hydrolyzing their membrane phospholipids. Whether PLA2G1B enhances or protects against mucosal injury and inflammation in intestinal bowel disease has not been explored previously. This study compares wild-type and Pla2g1b−/− mice in response to dextran sulfate sodium (DSS)-induced colitis to address this issue.

2. Results

2.1. Genetic Inactivation of PLA2G1B Protects against DSS-Induced Colitis

The role of PLA2G1B in inflammatory bowel disease was assessed by comparing wild-type C57BL/6J and Pla2g1b−/− mice in response to colonic epithelial cell injury induced by 5 days of oral DSS treatment [25]. The results showed minimal body weight loss in both groups during the initial 5-day period, although the differences between the wild-type and Pla2g1b−/− mice were significant (Figure 1A). Interestingly, while the wild-type mice continued to lose weight during the 5-day recovery period, the body weights of the Pla2g1b−/− mice stabilized during the recovery period, and they appeared to regain weight toward the end of the 10-day study period (Figure 1A). An analysis of the disease activity index (DAI) score revealed evidence of colitis in both groups, but the disease in the Pla2g1b−/− mice was significantly milder compared to that observed in the wild-type mice through the initial 5-day injury period as well as 5 days thereafter during the recovery period (Figure 1B). At the end of the study period, the colon lengths in the wild-type mice were significantly shorter than those observed in the Pla2g1b−/− mice (Figure 1C). A histological characterization of the colon revealed significantly less damage of the crypts, including a mostly preserved crypt architecture in the Pla2g1b−/− mice (Figure 1D).

2.2. Resistance of Pla2g1b−/− Mice to DSS-Induced Colitis Is Unrelated to Lysophospholipid Content in Colon

Our previous studies have shown that the resistance of Pla2g1b−/− mice to diet-induced obesity and hyperglycemia is due to reduced lysophospholipid levels in the intestinal lumen and their transport to the liver [18,19]. In view of the relationship between LPC levels and colitis in humans [6,7], we measured the LPC and lysophosphatidic acid (LPA) levels in the colons of wild-type and Pla2g1b−/− mice after the DSS treatment. In contrast to the lower LPC and LPA levels in the intestinal lumens of the Pla2g1b−/− mice under normal conditions [18,19], higher LPC and LPA levels were observed in the colons of the DSS-treated Pla2g1b−/− mice compared to the wild-type mice (Figure 2). These observations indicated that the PLA2G1B-catalyzed phospholipid conversion to lysophospholipid in the intestine plays a minimal role in phospholipid–lysophospholipid homeostasis in the colon. Moreover, the resistance of Pla2g1b−/− mice to DSS-induced colitis despite the elevated colonic LPC and LPA levels suggested that an increased lysophospholipid content in the colon is not sufficient for colitis pathogenesis.

2.3. PLA2G1B Inactivation Increases Intestinal Stem Cells

Previous studies have shown that PLA2G2A and PLA2G10 are normally expressed intracellularly in Paneth and Paneth/goblet-like cells along the digestive tract to inhibit intestinal stem cell function and differentiation for the maintenance of cell homeostasis. However, these enzymes can be secreted upon inflammation to inhibit intestinal stem cell growth [16]. Importantly, the inactivation of PLA2G10 in PLA2G2A-defective C57BL/6J mice was found to promote cell growth and improve recovery from inflammation to limit DSS-induced colitis [16]. Since PLA2G1B is an enzyme that is secreted into the intestinal lumen, we examined the intestines of wild-type and Pla2g1b−/− mice histologically and found increased numbers of Id1- and olfactomedin 4 (Olfm4)-positive intestinal stem and progenitor cells in the Pla2g1b−/− mice compared to the wild-type mice (Figure 3). The increased reservoir of intestinal stem and progenitor cells in the Pla2g1b−/− mice may be one factor that is responsible for the improved recovery of the intestinal epithelium and reduced colitis observed in these animals.

2.4. PLA2G1B Inactivation Increases Expression of Genes That Promote Epithelial Repair

Our data showing the improved recovery of DSS-induced colitis along with reduced colonic crypt damage and increased numbers of stem and progenitor cells in the intestines of Pla2g1b−/− mice compared to the wild-type mice suggest that PLA2G1B inactivation may be related to increased epithelial repair. To test this possibility, RNA was prepared from the colons of DSS-treated wild-type and Pla2g1b−/− mice to assess the expression of genes related to epithelial proliferation and repair. The results showed that the expression levels of liver receptor homolog-1 (LRH-1) was significantly higher in the DSS-treated Pla2g1b−/− mice compared to the wild-type mice (Figure 4A). LRH-1 is a nuclear receptor that has been previously shown to promote intestinal crypt cell renewal, and its reduced expression in the colon was correlated with inflammatory bowel disease in humans [26,27]. The mechanism underlying LRH-1 protection against colitis is due to its promotion of glucocorticoid synthesis [27], which leads to the increased expression of peroxisome proliferator-activated receptor-γ (PPARγ) and the downstream effects of PPARγ in the protection against colitis and inflammatory bowel disease [28,29,30,31]. Indeed, the PPARγ expression levels were also found to be higher in the colons of the Pla2g1b−/− mice compared to the wild-type mice (Figure 4B). Additionally, the tight junction proteins, Zonula Occludens 1 (ZO-1) and E-cadherin (CDH1), that are important for epithelial integrity maintenance [32,33] were also expressed at a higher levels in the colons of the DSS-treated Pla2g1b−/− mice compared to the wild-type mice (Figure 4C,D). Taken together, these results are consistent with the interpretation that PLA2G1B inactivation protects against DSS-induced colitis by accelerating epithelial repair.

2.5. PLA2G1B Inactivation Reduces DSS-Induced Inflammation

Another hallmark of colitis is an acute innate inflammatory response due to neutrophil and macrophage infiltration into the mucosa [25]. In particular, the elevated expression of macrophage inflammatory protein-2 (MIP2, also known as CXCL2) has been shown to correlate positively with disease severity [34]. In view of previous studies showing that PLA2G1B inactivation suppresses inflammation in chronic metabolic diseases [23], we explored whether the reduced colitis observed in the Pla2g1b−/− mice may also be due to the reduced innate inflammation in the colon. While a quantitative RT-PCR analysis did not reveal a difference in the expressions of macrophage gene markers, CD68 and EMR1, between the colons of the DSS-treated wild-type and Pla2g1b−/− mice (Figure 5A,B), the expressions of inflammatory cytokines such as CCL2/MCP1, CCL3/MIP-1α, CXCL1/KC, CXCL2/MIP2, IL-1β, and IL-6 were significantly lower in the colons of the DSS-treated Pla2g1b−/−mice compared to the wild-type mice (Figure 5C–H). Correspondingly, the plasma levels of CXCL1/KC, CXCL2/MIP2, IL-1β, and IL-6 were found to increase progressively in the wild-type mice after the DSS treatment, but their levels in the Pla2g1b−/− mice remained low throughout the experimental period after the DSS treatment (Figure 6). Taken together, these data indicated that PLA2G1B inactivation did not affect monocyte/macrophage infiltration into the colon in response to DSS-induced epithelial injury, but it reduced inflammatory cytokine production to limit inflammation and colitis.

2.6. PLA2G1B Directly Activates Inflammatory Cytokine Production in Myeloid Cells

The relationship between PLA2G1B and inflammatory cytokine production was explored in vitro by ascertaining the potential of a direct influence of exogenous PLA2G1B, mimicking the influence of PLA2G1B secreted into the intestinal and colonic lumen on cytokine expression by bone marrow-derived myeloid cells. For these experiments, bone marrow was obtained from wild-type C57BL/6J mice and differentiated into mature myeloid cells via incubation with granulocyte-macrophage colony-stimulating factor (GM-CSF) or macrophage colony-stimulating factor (M-CSF). The differentiated myeloid cells were then incubated with or without 10 µg/mL of bovine PLA2G1B for 3 h prior to RNA isolation for the RT-PCR analysis of gene expression. The results showed that exogenously added PLA2G1B elevated the expressions of the inflammatory cytokines, TNFα, MIP-1α, CXCL1, IL-1β, and MIP-2, by ~2–4 fold in the GM-CSF-activated myeloid cells (Figure 7A) and by ~8–12 fold in the M-CSF-activated myeloid cells (Figure 7B). These results suggested that, despite the presence of similar levels of macrophages in the colons of the DSS-treated wild-type and Pla2g1b−/− mice, significantly lower levels of proinflammatory cytokine expression were detected in the colons of the DSS-treated Pla2g1b−/− mice compared to the wild-type mice. These results suggest that the higher cytokine expression levels detected in the DSS-treated colons of wild-type mice compared to the Pla2g1b−/− mice were likely due to exogenous PLA2G1B secreted into the digestive tract, stimulating the macrophage inflammatory response in the wild-type mice.

3. Discussion

This study showed that PLA2G1B secreted by the pancreas into the gastrointestinal tract contributes to inflammatory bowel disease, and its inactivation in mice protects against DSS-induced inflammation and colitis. The effects of PLA2G1B on colitis are similar to those observed with PLA2G2A secreted predominantly by macrophages, in which its inhibition was shown to protect rats from chemically induced colitis [17,35]. The effects of these secretory phospholipases are in striking contrast to those observed with another secretory phospholipase, PLA2G10, secreted by colonic epithelial cells, which was shown to suppress colitis, and its deficiency led to increased DSS-induced inflammation and colitis [15]. The protective effect of PLA2G10 was attributed to its preference for the selective mobilization of ω-3 polyunsaturated fatty acids from membrane phospholipids [15], a property that was not observed with PLA2G1B.
One shared property of phospholipase A2 enzymes including PLA2G1B, PL2G2A, and PLA2G10 is the hydrolysis of phospholipids at the sn-2 position to produce one fatty acid and a lysophospholipid. Whereas the protective effect of PLA2G10 was attributed to the liberation of ω-3 polyunsaturated fatty acids, the colitis-promoting effect of PLA2G2A was attributed to the liberation of ω-6 polyunsaturated fatty acids and the subsequent generation of eicosanoids in the colon after macrophage infiltration into the tissue in response to DSS-induced injury [35]. However, we did not find a difference in the LPC and LPA levels in the colons of the DSS-treated wild-type and Pla2g1b−/− mice, thus indicating that PLA2G1B plays a minimal role in phospholipid hydrolysis in the colon. It is likely that other PLA2 enzymes that are highly expressed in colonic epithelial cells, such as PLA2G12A, PLA2G2D, PLA2G5, PLA2G10, and PLA2G12B [36], are responsible for generating the bulk of LPC and LPA in the colons of DSS-treated mice. Importantly, these data indicate that the increased LPC and LPA levels in the colon is not sufficient to drive colitis after DSS treatment. Furthermore, unlike the effects of PLA2G2A and PLA2G10, which increase colitis via LPC and LPA elevation, the protective effects of PLA2G1B inactivation on DSS-induced inflammation and colitis are not due to alterations in phospholipid remodeling in the colon.
The protective effects of PLA2G1B inactivation were most evident during the recovery phase after the cessation of the DSS treatment. These observations suggest that PLA2G1B inactivation either accelerates intestinal barrier regeneration after injury and/or reduces inflammation in the colon to promote repair. Our histological data revealed increased numbers of stem and progenitor cells in the intestines of the Pla2g1b−/− mice compared to the wild-type mice. In view of reports showing that intestinal stem cell activation promotes intestinal epithelial regeneration [37,38], the reduced colitis disease index observed in the Pla2g1b−/− mice may be due, at least in part, to the increased stem cell reservoir in their intestines that can be activated during injury to accelerate epithelial regeneration. The relationship between PLA2G1B inactivation and accelerated epithelial repair was supported by observations of increased expressions of genes responsible for epithelial repair such as LRH-1, PPARγ, ZO-1, and CDH1 in the colons of DSS-treated Pla2g1b−/− mice compared to the wild-type mice.
It is important to note that although the negative impact of PLA2G1B on intestinal epithelial repair is reminiscent of the influence of PLA2G2A on intestinal stem cell proliferation, epithelial cell repair, and DSS-induced colitis [16], the mechanism by which PLA2G1B and PLA2G2A regulate intestinal stem cell proliferation and epithelial regeneration may be quite different. Whereas PLA2G2A is expressed in intestinal Paneth cells and influences stem cell niche through both intracellular YAP1 activation and extracellular effects to promote Wnt signaling and inflammation [16], PLA2G1B is not expressed in the intestine but is secreted from pancreatic acinar cells into the intestinal lumen in response to food intake to aid lipid nutrient absorption [39]. It is possible that the undigested phospholipids in the intestinal lumen are responsible for increased enterocyte proliferation and the observed epithelial regeneration in the Pla2g1b−/− mice. Consistent with this hypothesis is the previous report that showed that the biliary phospholipids secreted into the intestinal lumen promote enterocyte proliferation via the activation of the nuclear receptor, LRH1 [40,41]. Additionally, extracellular phospholipid hydrolysis has been shown to be required for cholesterol uptake into intestinal cells [42]. The reduced cholesterol uptake may lead to a compensatory increase in endogenous cholesterol biosynthesis via the sterol regulatory element-binding protein (SREBP)-mediated pathway, a process that has also been linked to intestinal stem cell proliferation [43]. Whether PLA2G1B deficiency promotes stem cell proliferation and epithelial repair exclusively through LRH1 or if SREBP-mediated pathways are also involved will require additional comprehensive studies.
The current study also revealed reduced inflammatory cytokine production in the colons of the DSS-treated Pla2g1b−/− mice compared to the wild-type mice. The reduced colonic inflammation cannot be due entirely to the accelerated epithelial regeneration in the intestines of Pla2g1b−/− mice because comparable expression levels of CD68 and EMR1 indicated that a similar number of macrophages was present in the colons of both groups. Hence, the reduced expression of inflammatory cytokines in the Pla2g1b−/− mice suggested that PLA2G1B may have a direct influence on the macrophage inflammatory response. Our in vitro experiments using GM-CSF-derived myeloid cells that mimic the role of GM-CSF in macrophage defense and wound healing in the intestine [44], and M-CSF-differentiated bone marrow cells that specifically produce macrophages, revealed that exogenous PLA2G1B directly activates macrophages to secrete proinflammatory cytokines. It is likely that PLA2G1B activates proinflammatory cytokine secretion via these macrophages by binding to M-type phospholipase A2 receptors and the activation of signal transduction pathways similar to that observed in human lung macrophages [45]. These studies identified a direct contributory role of PLA2G1B in DSS-induced colonic inflammation. Thus, PLA2G1B inactivation may also suppress DSS-induced colitis by reducing inflammation in the colon. These results suggest that specific PLA2G1B inhibition may be a viable option for the treatment of acute colitis as well as other inflammatory diseases.

4. Materials and Methods

4.1. Animals

Wild-type C57BL/6J mice purchased from Jackson Laboratories (Bar Harbor, ME, USA) were used to establish a breeding colony in our institutional facility. The Pla2g1b−/− mice were generated in our laboratory and backcrossed with C57BL/6J mice for >10 generations to generate Pla2g1b−/− mice in C57BL/6J background, as described in [18]. The C57BL/6J and Pla2g1b−/− mouse colonies were maintained in a temperature- and humidity-controlled room with a 12 h light/dark cycle. The animals were fed rodent chow (#5053; Purina Pico Labs, Cincinnati, OH, USA) with free water access. All experiments were performed according to experimental protocols approved by the institutional animal care and use committee at the University of Cincinnati in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.

4.2. DSS-Induced Colitis

Male mice were given water with or without 3% (w/v) of 36k–50k molecular weight DSS (MP Biomedicals, Santa Ana, CA, USA) for 5 days followed by regular water without DSS for another 5 days, similar to the established protocol used to examine colitis in mice [46]. Body weights were measured daily. Stool consistency and the presence of occult blood was determined daily using the Sure-VueTM Fecal Occult Blood Slide Test System (23-038031, ThermoFisher, Cincinnati, OH, USA). Each parameter was assigned a score to determine the disease activity index (Table 1).

4.3. Colon Histology

Distal colon tissues were fixed in 10% formalin, processed, embedded in paraffin, and stained with hematoxylin and eosin. Images were taken using an Olympus BX61 microscope. Pathological score was determined based on crypt damage, depth of injury, and severity of inflammatory cell infiltration. The score was multiplied by a factor reflecting the percentage of affected area and added to obtain a total score (Table 2).

4.4. Colonic Lysophosphatidylcholine (LPC) and Lysophosphatidic Acid (LPA) Measurements

Colonic LPC and LPA contents were determined by flushing the isolated colons with phosphate-buffered saline and then flash-frozen at −80 °C. The colon tissues were thawed in buffer containing 50 mM Tris-Cl, pH 7.4, 150 mM NaCl, and 10 mM EDTA. The samples were extracted three times with n-butanol-saturated water, as described in [47]. The butanol fractions were dried under N2 stream and then rehydrated for determination of LPC and LPA levels with commercially available ELISA assay kits (MyBioSource, San Diego, CA, USA; #MBS2031889 and #MBS2024826, respectively).

4.5. Intestinal Stem and Progenitor Cell Identification

Intestine samples were fixed overnight in 10% neutral-buffered formalin and then embedded in paraffin for preparation of thin sections. The thin section slides were incubated with primary antibodies, which were rabbit anti-Olfm4 (1:500 dilution; Cell Signaling, Danvers, MA, USA; #39141) or rabbit anti-Id1 (1:200; CalBioreagents, San Mateo, CA, USA; #M082), to identify intestinal stem and progenitor cells, and then visualized using a VectaStain Elite ABC kit (Vector Labs, Newark, CA, USA; PK-6101). The numbers of stem and progenitor cells were assessed from ~100 crypts (N = 8 mice per group), as described in [43].

4.6. RNA Expression in Colon and Bone Marrow-Derived Myeloid Cells

RNA was isolated from the colons of DSS-treated mice or bone marrow-derived myeloid cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA;) and Direct-zol RNA miniprep kit (Zymo Research, Irvine, CA, USA;). RNA extracted from colons was also subjected to lithium chloride precipitation to remove polysaccharides. cDNA was synthesized from the extracted RNA using the qScript cDNA Synthesis Kit (QuantaBio, Beverley, MA, USA). Quantitative real-time PCR (RT-PCR) was performed with a StepOnePlus Fast thermocycler using Fast SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA, USA). Sequence-specific primers are listed in Table 3. Expression levels of mRNA were normalized to cyclophilin using the ΔΔCT analysis method.

4.7. Plasma Cytokine Measurement

Blood was collected from DSS-treated mice after a 4 h fast for plasma preparation. Inflammatory cytokines in the plasma were measured using commercially available ELISA kits for CXCL1 (R&D Systems, Minneapolis, MN, USA; DY453-05), MIP-2 (ThermoFisher, Cincinnati, OH, USA; EMCXCL2), IL-1β (ThermoFisher, BMS6002), and IL-6 (R&D Systems, M6000B).

4.8. PLA2G1B-Induced Cytokine Expression In Vitro

Bone marrow cells isolated from tibias and femurs of wild-type C57BL/6J mice were flushed with Hanks’ balanced salt solution, subjected to red blood cell lysis (eBioscience, San Diego, CA, USA; 00-4300-54) for 5 min at room temperature, and passed through a 40 µm cell strainer. The isolated cells were cultured in the presence of 20 ng/mL GM-CSF (Peprotech, Cranbury, NJ, USA; 315-03) or 20% L929-conditioned media as source of M-CSF for 7 days to induce differentiation of monocytes into mature myeloid cells with dendritic cell and macrophage characteristics. The mature myeloid cells were then incubated with or without 10 µg/mL bovine PLA2G1B (Sigma Aldrich, Burlington, MA, USA; P8913) for 3 h prior to RNA isolation. Expression levels of inflammatory cytokines were determined via RT-PCR as described above.

4.9. Statistical Analysis

All data were expressed as the mean ± SD. Statistical analysis was performed using Graphic Prism version 5 software (GraphPad Software, Boston, MA, USA). Normality was examined using the Shapiro–Wilk test. All data showed parametric distribution and were evaluated for differences using Student’s t-test. Differences at p < 0.05 were considered statistically significant.

5. Conclusions

This study shows that PLA2G1B inactivation reduces DSS-induced colitis in mice by increasing the stem and progenitor cell populations in the intestine to accelerate intestinal epithelial repair as well as by reducing the proinflammatory responses of myeloid cells in the colon. Although these results may be interpreted to suggest that PLA2G1B-specific inhibition is a potential therapeutic option for inflammatory bowel disease management, a limitation of this study is that the study was conducted in mouse models. The translation of these results to a clinical setting requires direct preclinical experiments in humans. Moreover, whether increased stem and progenitor cell populations in the intestine with PLA2G1B inactivation may also increase cancer risk also needs to be addressed.

Author Contributions

Conceptualization, D.Y.H.; methodology, A.M.H., P.R.W. and A.J.; data analysis, A.M.H., A.J., P.R.W. and D.Y.H.; investigation, A.M.H., P.R.W. and A.J.; resources, D.Y.H.; data curation, A.M.H., P.R.W. and A.J.; writing—original draft preparation, D.Y.H.; writing—review and editing, A.J., A.M.H., P.R.W. and D.Y.H.; funding acquisition, D.Y.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Institutes of Health, grant number RO1 DK112657.

Institutional Review Board Statement

The animal study protocol was approved by the Institutional Animal Care and Use Committee Review Board of the University of Cincinnati (protocol number 20-06-17-02; approval date 19 October 2020) in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.

Data Availability Statement

The data supporting this study are available within the article and from the corresponding author (David Y. Hui, huidy@ucmail.uc.edu) upon request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Scaldaferri, F.; Fiocchi, C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J. Dig. Dis. 2007, 8, 171–178. [Google Scholar] [CrossRef]
  2. Mentella, M.C.; Scaldaferri, F.; Pizzoferrato, M.; Gasbarrini, A.; Miggiano, G.A.D. Nutrition, IBD, and gut microbiota: A review. Nutrients 2020, 12, 944. [Google Scholar] [CrossRef]
  3. Sakamoto, N.; Kono, S.; Wakai, K.; Fukuda, Y.; Satomi, M.; Shimoyama, T.; Inaba, Y.; Miyake, Y.; Sasaki, S.; Okamoto, K.; et al. Dietary risk factors for inflammatory bowel disease: A multicenter case-control study in Japan. Inflamm. Bowel Dis. 2005, 11, 154–163. [Google Scholar] [CrossRef]
  4. Gearry, R.B.; Richardson, A.K.; Frampton, C.M.; Dodgshun, A.J.; Barclay, M.L. Population based cases control study of inflammatory bowel disease risk factors. J. Gastroenterol. Hepatol. 2010, 25, 325–333. [Google Scholar] [CrossRef]
  5. Scoville, E.A.; Allaman, M.M.; Brown, C.T.; Motley, A.K.; Horst, S.N.; Williams, C.S.; Koyama, T.; Zhao, Z.; Adams, D.W.; Beaulieu, D.B.; et al. Alterations in lipid, amino acid, and energy metabolism distinguish Crohn’s disease from ulcerative colitis and control subjects by serum metabolomic profiling. Metabolomics 2018, 14, 17. [Google Scholar] [CrossRef]
  6. Diab, J.; Hansen, T.; Goll, R.; Stenlund, H.; Ahnlund, M.; Jensen, E.; Moritz, T.; Florholmen, J.; Forsdahl, G. Lipidomics in ulcerative colitis reveal alteration in mucosal lipid composition associated with the disease state. J. Inflamm. Bowel Dis. 2019, 25, 1780–1787. [Google Scholar] [CrossRef]
  7. Braun, A.; Treede, I.; Gotthardt, D.; Tietje, A.; Zahn, A.; Ruhwald, R.; Schoenfeld, U.; Welsch, T.; Kienle, P.; Erben, G.; et al. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: A clue to pathogenesis. Inflamm. Bowel Dis. 2009, 15, 1705–1720. [Google Scholar] [CrossRef]
  8. Dennis, E.A.; Cao, J.; Hsu, Y.-H.; Magrioti, V.; Kokotos, G. Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev. 2011, 111, 6130–6185. [Google Scholar] [CrossRef]
  9. Wu, W.-H.; Li, W.-X.; Huang, C.-H. Phospholipase A2 a nonnegligible enzyme superfamily in gastrointestinal diseases. Biochimie 2022, 194, 79–95. [Google Scholar] [CrossRef]
  10. Sonnweber, T.; Pizzini, A.; Nairz, M.; Weiss, G.; Tancevski, I. Arachidonic acid metabolites in cardiovascular and metabolic diseases. Int. J. Mol. Sci. 2018, 19, 3285. [Google Scholar] [CrossRef]
  11. Jiao, L.; Inhoffen, J.; Gan-Schreier, H.; Tuma-Kellner, S.; Stremmel, W.; Sun, Z.; Chamulitrat, W. Deficiency of Group VIA phospholipase A2 (iPLA2b) renders susceptibility for chemical-induced colitis. Dig. Dis. Sci. 2015, 60, 3590–3602. [Google Scholar] [CrossRef] [PubMed]
  12. Rosengarten, M.; Hadad, N.; Solomonov, Y.; Lamprecht, S.; Levy, R. Cytosolic phospholipase A2a has a crucial role in the pathogenesis of DSS-induced colitis in mice. Eur. J. Immunol. 2016, 46, 400–408. [Google Scholar] [CrossRef] [PubMed]
  13. Zhai, L.; Huang, T.; Xiao, H.-T.; Wu, P.-G.; Lin, C.-Y.; Ning, Z.-W.; Zhao, L.; Kwan, H.Y.A.; Hu, X.-J.; Wong, H.L.X.; et al. Berberine suppresses colonic inflammation in dextran sulfate sodium-induced murine colitis through inhibition of cytosolic phospholipase A2 activity. Front. Pharmacol. 2020, 11, 576496. [Google Scholar] [CrossRef] [PubMed]
  14. Murase, R.; Taketomi, Y.; Miki, Y.; Nishito, Y.; Saito, M.; Fukami, K.; Yamamoto, K.; Murakami, M. Group III phospholipase A2 promotes colitis and colorectal cancer. Sci. Rep. 2017, 7, 12261. [Google Scholar] [CrossRef]
  15. Murase, R.; Sato, H.; Yamamoto, K.; Ushida, A.; Nishito, Y.; Ikeda, K.; Kobayashi, T.; Yamamoto, T.; Taketomi, Y.; Murakami, M. Group X secreted phospholipase A2 release w3 polyunsaturated fatty acids, suppresses colitis, and promotes sperm fertility. J. Biol. Chem. 2016, 291, 6895–6911. [Google Scholar] [CrossRef]
  16. Schewe, M.; Franken, P.F.; Sacchetti, A.; Schmitt, M.; Joosten, R.; Bottcher, R.; van Royen, M.E.; Jeammet, L.; Payre, C.; Scott, P.M.; et al. Secreted phospholipase A2 are intestinal stem cell niche factors with distinct roles in homeostasis, inflammation, and cancer. Cell Stem Cell 2016, 19, 38–51. [Google Scholar] [CrossRef]
  17. Woodruff, T.M.; Arumugam, T.V.; Shiels, I.A.; Newman, M.L.; Ross, P.A.; Reid, R.C.; Fairlie, D.P.; Taylor, S.M. A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. Int. Immunopharmacol. 2005, 5, 883–892. [Google Scholar] [CrossRef]
  18. Labonté, E.D.; Kirby, R.J.; Schildmeyer, N.M.; Cannon, A.M.; Huggins, K.W.; Hui, D.Y. Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia. Diabetes 2006, 55, 935–941. [Google Scholar] [CrossRef]
  19. Labonté, E.D.; Pfluger, P.T.; Cash, J.G.; Kuhel, D.G.; Roja, J.C.; Magness, D.P.; Jandacek, R.J.; Tschop, M.H.; Hui, D.Y. Postprandial lysophospholipid suppresses hepatic fatty acid oxidation: The molecular link between group 1B phospholipase A2 and diet-induced obesity. FASEB J. 2010, 24, 2516–2524. [Google Scholar] [CrossRef]
  20. Hollie, N.I.; Cash, J.G.; Matlib, M.A.; Wortman, M.; Basford, J.E.; Abplanalp, W.; Hui, D.Y. Micromolar changes in lysophosphatidylcholine concentration cause minor effects on mitochondrial permeability but major alterations in function. Biochim. Biophys. Acta 2014, 1841, 888–895. [Google Scholar] [CrossRef]
  21. Hollie, N.I.; Hui, D.Y. Group 1B phospholipase A2 deficiency protects against diet-induced hyperlipidemia in mice. J. Lipid Res. 2011, 52, 2005–2011. [Google Scholar] [CrossRef] [PubMed]
  22. Hollie, N.I.; Konaniah, E.S.; Goodin, C.; Hui, D.Y. Group 1B phospholipase A2 inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice. Atherosclerosis 2014, 234, 377–380. [Google Scholar] [CrossRef] [PubMed]
  23. Hui, D.Y. Group 1B phospholipase A2 in metabolic and inflammatory disease modulation. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2019, 1846, 784–788. [Google Scholar] [CrossRef] [PubMed]
  24. Entwistle, L.J.; Pelly, V.S.; Coomes, S.M.; Kannan, Y.; Perez-Lloret, J.; Czieso, S.; Silva dos Santos, M.; MacRae, J.I.; Collinson, L.; Sesay, A.; et al. Epithelial-cell-derived phospholipase A2 group 1b is an endogenous anthelmintic. Cell Host Microbe 2017, 22, 484–493. [Google Scholar] [CrossRef]
  25. Okayasu, I.; Hatakeyama, S.; Yamada, M.; Ohkusa, T.; Inagaki, Y.; Nakaya, R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98, 694–701. [Google Scholar] [CrossRef]
  26. Bayrer, J.R.; Wang, H.; Nattiv, R.; Suzawa, M.; Escusa, H.S.; Fletterick, R.J.; Klein, O.D.; Moore, D.D.; Ingraham, H.A. LRH-1 mitigates intestinal inflammatory disease by maintaining epithelial homeostasis and cell survival. Nat. Commun. 2018, 9, 4055. [Google Scholar] [CrossRef]
  27. Coste, A.; Dubuquoy, L.; Barnouin, R.; Annicotte, J.-S.; Magnier, B.; Notti, M.; Corazza, N.; Antal, M.C.; Metzger, D.; Desreumaux, P.; et al. LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 2007, 104, 13098–13103. [Google Scholar] [CrossRef]
  28. Bouguen, G.; Langlois, A.; Djouina, M.; Branche, J.; Koriche, D.; Dewaeles, E.; Mongy, A.; Auwerx, J.; Columbel, J.-F.; Desreumaux, P.; et al. Intestinal steroidogenesis controls PPARg expression in the colon and is impaired during ulcerative colitis. Gut 2015, 64, 901–910. [Google Scholar] [CrossRef]
  29. Adachi, M.; Kurotani, R.; Morimura, K.; Shah, Y.M.; Sanford, M.; Madison, B.B.; Gumucio, D.L.; Marin, H.E.; Peters, J.M.; Young, H.A.; et al. Peroxisome proliferator activated receptor g in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006, 55, 1104–1113. [Google Scholar] [CrossRef]
  30. Su, C.G.; Wen, X.; Bailey, S.T.; Jiang, W.; Rangwala, S.M.; Keilbaugh, S.A.; Flanigan, A.; Murthy, S.; Lazar, M.A.; Wu, G.D. A novel therapy for colitis utilizing PPAR-g ligands to inhibit the epithelial inflammatory response. J. Clin. Investig. 1999, 104, 383–389. [Google Scholar] [CrossRef]
  31. Fang, J.; Wang, H.D.; Xue, Z.; Cheng, Y.; Zhang, X. PPARg: The central mucus barrier coordinator in ulcerative colitis. Inflamm. Bowel Dis. 2021, 27, 732–741. [Google Scholar] [CrossRef] [PubMed]
  32. Kuo, W.-T.; Odenwald, M.A.; Turner, J.R.; Zuo, L. Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival. Ann. N. Y. Acad. Sci. 2022, 1514, 21–33. [Google Scholar] [CrossRef] [PubMed]
  33. Schnoor, M. E-cadherin is important for the maintenance of intestinal epithelial homeostasis under basal and inflammatory conditions. Dig. Dis. Sci. 2015, 60, 816–818. [Google Scholar] [CrossRef] [PubMed]
  34. Frantz, A.L.; Bruno, M.E.C.; Rogier, E.W.; Tuna, H.; Cohen, D.A.; Bondada, S.; Chelvarajan, R.L.; Brandon, J.A.; Jennings, C.D.; Kaetzel, C.S. Multifactorial patterns of gene expression in colonic epithelial cells predict disease phenotypes in experimental colitis. Inflamm. Bowel Dis. 2012, 18, 2138–2148. [Google Scholar] [CrossRef]
  35. Tomita, Y.; Jyoyama, H.; Kobayashi, M.; Kuwabara, K.; Furue, S.; Ueno, M.; Yamada, K.; Ono, T.; Teshirogi, T.; Nomura, K.; et al. Role of group IIA phospholipase A2 in rat colitis induced by dextran sulfate sodium. Eur. J. Pharmacol. 2003, 472, 147–158. [Google Scholar] [CrossRef]
  36. Mournier, C.M.; Wendum, D.; Greenspan, E.; Flejou, J.-F.; Rosenberg, D.W.; Lambeau, G. Distinct expression pattern of the full set of secreted phospholipase A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate. Br. J. Cancer 2008, 98, 587–595. [Google Scholar] [CrossRef]
  37. Barker, N. Adult intestinal stem cells: Critical drivers of epithelial homeostasis and regeneration. Nat. Rev. Mol. Cell Biol. 2014, 15, 19–33. [Google Scholar] [CrossRef]
  38. Sorrentino, G.; Perino, A.; Yildiz, E.; El Alam, G.; Bou Sleiman, M.; Gioiello, A.; Pellicciari, R.; Schoonjans, K. Bile acids signal via TGR5 to activate intestinal stem cells and epithelial regeneration. Gastroenterology 2020, 159, 956–968. [Google Scholar] [CrossRef]
  39. Borgström, B. Importance of phospholipids, pancreatic phospholipase A2 and fatty acid for the digestion of dietary fat. In vitro experiments with the porcine enzymes. Gastroenterology 1980, 78, 954–962. [Google Scholar] [CrossRef]
  40. Petruzzelli, M.; Piccinin, E.; Pinto, C.; Peres, C.; Bellafante, E.; Moschetta, A. Biliary phospholipids sustain enterocyte proliferation and intestinal tumor progression via nuclear receptor LRH1 in mice. Sci. Rep. 2016, 6, 39278. [Google Scholar] [CrossRef]
  41. Zerlotin, R.; Arconzo, M.; Piccinin, E.; Moschetta, A. Another one bites the gut: Nuclear receptor LRH-1 in intestinal regeneration and cancer. Cancers 2021, 13, 896. [Google Scholar] [CrossRef] [PubMed]
  42. Mackay, K.; Starr, J.R.; Lawn, R.M.; Ellsworth, J.L. Phosphatidylcholine hydrolysis is required for pancreatic cholesterol esterase- and phospholipase A2-facilitated cholesterol uptake into intestinal Caco-2 cells. J. Biol. Chem. 1997, 272, 13380–13389. [Google Scholar] [CrossRef] [PubMed]
  43. Wang, B.; Rong, X.; Palladino, E.N.D.; Wang, J.; Fogelman, A.M.; Martin, M.G.; Alrefai, W.A.; Ford, D.A.; Tontonoz, P. Phospholipid remodeling and cholesterol availability regulate intestinal stemness and tumorigenesis. Cell Stem Cell 2018, 22, 206–220. [Google Scholar] [CrossRef] [PubMed]
  44. Castro-Dopico, T.; Fleming, A.; Dennison, T.W.; Ferdinand, J.R.; Harcourt, K.; Stewart, B.J.; Cader, Z.; Tuong, Z.K.; Jing, C.; Lok, L.S.C.; et al. GM-CSF calibrates macrophage defense and wound healing programs during intestinal infection and inflammation. Cell Rep. 2020, 32, 107857. [Google Scholar] [CrossRef]
  45. Granata, F.; Petraroli, A.; Biolard, E.; Bezzine, S.; Bollinger, J.G.; Del Vecchio, L.; Gelb, M.H.; Lambeau, G.; Marone, G.; Triggiani, M. Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the M type receptor. J. Immunol. 2005, 174, 464–474. [Google Scholar] [CrossRef]
  46. Cooper, H.S.; Murthy, S.N.S.; Shah, R.S.; Sedergran, D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Investig. 1993, 69, 238–249. [Google Scholar]
  47. Cash, J.G.; Konaniah, E.S.; Hegde, N.; Kuhel, D.G.; Watanabe, M.; Romick-Rosendale, L.; Hui, D.Y. Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission. Mol. Metab. 2018, 16, 55–64. [Google Scholar] [CrossRef]
Ijms 24 16155 g001
Figure 1. Inactivation of PLA2G1B reduces DSS-induced colitis in mice. Drinking water supplemented with 3% DSS was administered to 12-week-old male wild-type C57BL/6J (WT, N = 27) and Pla2g1b−/− (N = 26) mice for 5 days followed by water without DSS for 5 additional days. (A) Body weight loss and (B) disease activity index were monitored over a 10-day period. Data = mean ± SEM; # p < 0.01 versus WT group. (C) Colon lengths (each block = 0.6 cm) in WT and Pla2g1b−/− mice as well as (D) pathological scores in WT (N = 10) and Pla2g1b−/− (N = 10) mice were assessed at the end of the 10-day period. Statistical significance was evaluated using Student’s t-test with the p values as indicated.
Figure 1. Inactivation of PLA2G1B reduces DSS-induced colitis in mice. Drinking water supplemented with 3% DSS was administered to 12-week-old male wild-type C57BL/6J (WT, N = 27) and Pla2g1b−/− (N = 26) mice for 5 days followed by water without DSS for 5 additional days. (A) Body weight loss and (B) disease activity index were monitored over a 10-day period. Data = mean ± SEM; # p < 0.01 versus WT group. (C) Colon lengths (each block = 0.6 cm) in WT and Pla2g1b−/− mice as well as (D) pathological scores in WT (N = 10) and Pla2g1b−/− (N = 10) mice were assessed at the end of the 10-day period. Statistical significance was evaluated using Student’s t-test with the p values as indicated.
Ijms 24 16155 g001
Ijms 24 16155 g002
Figure 2. Colonic contents of (A) LPC and (B) LPA in wild-type (WT, N = 8) and Pla2g1b−/− (N = 8) mice after DSS-induced injury. Phospholipids and lysophospholipids were extracted from colons for analysis. Data are shown as mean ± SD with p values evaluated using Student’s t-test, as indicated.
Figure 2. Colonic contents of (A) LPC and (B) LPA in wild-type (WT, N = 8) and Pla2g1b−/− (N = 8) mice after DSS-induced injury. Phospholipids and lysophospholipids were extracted from colons for analysis. Data are shown as mean ± SD with p values evaluated using Student’s t-test, as indicated.
Ijms 24 16155 g002
Ijms 24 16155 g003
Figure 3. PLA2G1B inactivation increased stem and progenitor cell population in the intestine. Intestines of wild-type (WT, N = 8) and Pla2g1b−/− (N = 8) mice were immunostained with antibodies against Id1 (A) or Olfm4 (B) to identify intestinal stem and progenitor cells. Representative images (scale bar = 100 µm) and mean ± SD of data for stem cells per 100 crypts are shown. Differences were evaluated using Student’s t-test with p values, as indicated.
Figure 3. PLA2G1B inactivation increased stem and progenitor cell population in the intestine. Intestines of wild-type (WT, N = 8) and Pla2g1b−/− (N = 8) mice were immunostained with antibodies against Id1 (A) or Olfm4 (B) to identify intestinal stem and progenitor cells. Representative images (scale bar = 100 µm) and mean ± SD of data for stem cells per 100 crypts are shown. Differences were evaluated using Student’s t-test with p values, as indicated.
Ijms 24 16155 g003
Ijms 24 16155 g004
Figure 4. PLA2G1B inactivation promotes expression of epithelial repair genes. Total RNA was prepared from the colons of DSS-treated wild-type (N = 8) and Pla2g1b−/− (N = 10) mice. RT-PCR was performed to assess expression levels of (A) LRH-1, (B) PPARγ, (C) ZO-1, and (D) CDH1 using cyclophilin (CypA) as the control. Data represent mean ± SD with p values indicated as determined using Student’s t-test.
Figure 4. PLA2G1B inactivation promotes expression of epithelial repair genes. Total RNA was prepared from the colons of DSS-treated wild-type (N = 8) and Pla2g1b−/− (N = 10) mice. RT-PCR was performed to assess expression levels of (A) LRH-1, (B) PPARγ, (C) ZO-1, and (D) CDH1 using cyclophilin (CypA) as the control. Data represent mean ± SD with p values indicated as determined using Student’s t-test.
Ijms 24 16155 g004
Ijms 24 16155 g005
Figure 5. PLA2G1B inactivation reduces inflammatory cytokine expression in colons of DSS-treated mice. Total RNA was prepared from the colons of DSS-treated wild-type (WT, N = 9) and Pla2g1b−/− mice (N = 7). RT-PCR was performed to assess expression levels of (A) CD68, (B) EMR1, (C) MCP-1, (D) MIP-1α, (E) MIP-2, (F) CXCL1, (G) IL-1β, and (H) IL-6. The data represent mean ± SD with p values determined using Student’s t-test, as indicated. n.s. = not significant.
Figure 5. PLA2G1B inactivation reduces inflammatory cytokine expression in colons of DSS-treated mice. Total RNA was prepared from the colons of DSS-treated wild-type (WT, N = 9) and Pla2g1b−/− mice (N = 7). RT-PCR was performed to assess expression levels of (A) CD68, (B) EMR1, (C) MCP-1, (D) MIP-1α, (E) MIP-2, (F) CXCL1, (G) IL-1β, and (H) IL-6. The data represent mean ± SD with p values determined using Student’s t-test, as indicated. n.s. = not significant.
Ijms 24 16155 g005
Ijms 24 16155 g006
Figure 6. PLA2G1B inactivation lowers inflammatory cytokines in plasma of DSS-treated mice. Wild-type (WT) and Pla2g1b−/− mice (N = 8–10 in each group) were treated with DSS-supplemented water for 5 days. Plasma was collected at day 5 and day 10 (5 days after DSS treatment) for ELISA determination of (A) CXCL1, (B) MIP-2, (C) IL-1β, and (D) IL-6. The data represent mean ± SD with significance evaluated using Student’s t-test, as indicated.
Figure 6. PLA2G1B inactivation lowers inflammatory cytokines in plasma of DSS-treated mice. Wild-type (WT) and Pla2g1b−/− mice (N = 8–10 in each group) were treated with DSS-supplemented water for 5 days. Plasma was collected at day 5 and day 10 (5 days after DSS treatment) for ELISA determination of (A) CXCL1, (B) MIP-2, (C) IL-1β, and (D) IL-6. The data represent mean ± SD with significance evaluated using Student’s t-test, as indicated.
Ijms 24 16155 g006
Ijms 24 16155 g007
Figure 7. PLA2G1B directly elevates inflammatory cytokine production via myeloid cells. Bone marrow cells isolated from wild-type C57BL/6J mice were incubated with (A) GM-CSF or (B) M-CSF to induce differentiation into mature myeloid cells. The myeloid cells were incubated with (red bars) or without (black bars) 10 µg/mL PLA2G1B for 3 h prior to RNA isolation. RT-PCR was performed to assess expression of the selected inflammatory cytokine genes as indicated. The # symbol indicates significant difference from wild-type group at p < 0.01 (N = 10 biological replicates), as determined using Student’s t-test.
Figure 7. PLA2G1B directly elevates inflammatory cytokine production via myeloid cells. Bone marrow cells isolated from wild-type C57BL/6J mice were incubated with (A) GM-CSF or (B) M-CSF to induce differentiation into mature myeloid cells. The myeloid cells were incubated with (red bars) or without (black bars) 10 µg/mL PLA2G1B for 3 h prior to RNA isolation. RT-PCR was performed to assess expression of the selected inflammatory cytokine genes as indicated. The # symbol indicates significant difference from wild-type group at p < 0.01 (N = 10 biological replicates), as determined using Student’s t-test.
Ijms 24 16155 g007
Table 1. Disease activity index.
Table 1. Disease activity index.
ScoreWeight LossStool ConsistencyBlood in Stool
0NoneNormal pelletsNone
11–5%Slightly loose but shapedHemoccult positive
25–10%Loose pelletsVisible slight bleeding
310–15%Loose feces and no shapeObvious bleeding, no adhesion around anus
4>15%DiarrheaGross bleeding, blood encrustation around anus
Table 2. Colon histology score.
Table 2. Colon histology score.
Histology GradeAreaImmune Cell Infiltration
0Normal morphology×10–25%0None
1<1/3 crypt damage×226–50%1Crypt base
2Loss of crypt×351–75%2Mucosa
3Crypt and epithelium loss×476–100%3Submucosa
Table 3. Primers used for qPCR.
Table 3. Primers used for qPCR.
NameForward PrimerReverse Primer
CyclophilinTCATGTGCCAGGGTGGTGACCCATTCAGTCTTGGCAGTGC
CD68TTTCTCCAGCTGTTCACCTTGACCCGAAGTGTCCCTTGTCA
EMR1TGTCTGACAATTGGGATCTGCCCTATACGTTCCGAGAGTGTTGTGGCA
MCP-1CTTCCTCCACCACCATGCACCAGCCGGCAACTGTGA
MIP-1αTTTGAAACCAGCAGCCTTTGCTCCTCAGGCATTCAGTTCCAGGTCAGT
MIP-2CCCTCAACGGAAGAACCAAAAGGCACATCAGGTACGATCCA
CXCL1TGGCTGGGATTCACCTCAAGAACATGTGGCTATGACTTCGGTTTGGGT
IL-1βCTACAGGCTCCGAGATGAACAACTCCATTGAGGTGGAGAGCTTTC
IL-6CCGGGAACGAAAGAGAAGCTGCGCTTGTGGAGAAGGAGTT
TNFαATCCGCGACGTGGAACTGACCGCCTGGAGTTCTGGAA
PPARγCTGCAGGCCCTGGAACTGCGATCTGCCTGAGGTCTGTCA
LRH-1TCACATCTCCCATTAGCATGACAGGAAAGTGACCATAGGGTTGGTAA
ZO-1CCTCCGTTGCCCTCACAGTAGGGCGCCCTTGGAATG
CDH1TGTGGGTCAGGAAATCACATCTTCCGATACGTGATCTTCTGATCCA
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Haller, A.M.; Wolfkiel, P.R.; Jaeschke, A.; Hui, D.Y. Inactivation of Group 1B Phospholipase A2 Enhances Disease Recovery and Reduces Experimental Colitis in Mice. Int. J. Mol. Sci. 2023, 24, 16155. https://doi.org/10.3390/ijms242216155

AMA Style

Haller AM, Wolfkiel PR, Jaeschke A, Hui DY. Inactivation of Group 1B Phospholipase A2 Enhances Disease Recovery and Reduces Experimental Colitis in Mice. International Journal of Molecular Sciences. 2023; 24(22):16155. https://doi.org/10.3390/ijms242216155

Chicago/Turabian Style

Haller, April M., Patrick R. Wolfkiel, Anja Jaeschke, and David Y. Hui. 2023. "Inactivation of Group 1B Phospholipase A2 Enhances Disease Recovery and Reduces Experimental Colitis in Mice" International Journal of Molecular Sciences 24, no. 22: 16155. https://doi.org/10.3390/ijms242216155

APA Style

Haller, A. M., Wolfkiel, P. R., Jaeschke, A., & Hui, D. Y. (2023). Inactivation of Group 1B Phospholipase A2 Enhances Disease Recovery and Reduces Experimental Colitis in Mice. International Journal of Molecular Sciences, 24(22), 16155. https://doi.org/10.3390/ijms242216155

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop